308 results on '"Bogaerts, Jan"'
Search Results
2. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting
3. Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort
4. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer
5. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
6. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
7. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial
8. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
9. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
10. ‘Mind the gap’ between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research
11. Societal challenges of precision medicine: Bringing order to chaos
12. A population-based approach to compare patient-reported outcomes of long-term Hodgkin’s lymphoma survivors according to trial participation : a joint study from the Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship registry and European Organisation for Research and Treatment of Cancer
13. Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response
14. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
15. Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
16. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
17. Why Do Clinical Trials Fail?
18. Imaging endpoints for clinical trial use: a RECIST perspective
19. Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response
20. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
21. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)
22. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
23. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
24. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
25. OPINION: RECIST — learning from the past to build the future
26. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC‐Netherlands Cancer Registry linked data with 20 years of follow‐up
27. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial
28. The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions
29. 50 years of the EORTC and the central role of the EORTC Headquarters
30. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
31. Pattern of care in locally advanced breast cancer: Focus on local therapy
32. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
33. Cavitation: a blessing in disguise? New method to establish vulnerability curves and assess hydraulic capacitance of woody tissues
34. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data
35. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial
36. Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial
37. The dream and reality of histology agnostic cancer clinical trials
38. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98†
39. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study
40. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902
41. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
42. A pipeline row operation method of CMOS image sensors
43. Total dose and displacement damage effects in a radiation-hardened CMOS APS
44. 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT
45. High-exposure-durability, high-quantum-efficiency (>90%) backside-illuminated soft-X-ray CMOS sensor
46. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
47. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
48. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group
49. Does Salvage Therapy Influence Outcome?
50. Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.